Free Trial

Russell Investments Group Ltd. Purchases 24,428 Shares of Glaukos Corporation $GKOS

Glaukos logo with Medical background

Key Points

  • Russell Investments Group Ltd. increased its stake in Glaukos Corporation by 174.9%, now owning approximately 0.07% of the company, valued at about $3.8 million.
  • Glaukos Corporation has received mixed analyst ratings, with target prices ranging from $72.00 to $134.00, and a consensus rating of "Moderate Buy".
  • The company reported a revenue increase of 29.7% year-over-year, despite a reported EPS of ($0.24), which exceeded expectations.
  • Need better tools to track Glaukos? Try 5 Weeks of MarketBeat All Access for $5. Start Portfolio Tracking Now.

Russell Investments Group Ltd. boosted its holdings in Glaukos Corporation (NYSE:GKOS - Free Report) by 174.9% during the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 38,393 shares of the medical instruments supplier's stock after acquiring an additional 24,428 shares during the quarter. Russell Investments Group Ltd. owned 0.07% of Glaukos worth $3,779,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in GKOS. Dimensional Fund Advisors LP lifted its position in Glaukos by 9.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 312,314 shares of the medical instruments supplier's stock valued at $46,828,000 after acquiring an additional 26,540 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new position in shares of Glaukos during the 4th quarter worth approximately $182,000. MetLife Investment Management LLC lifted its position in shares of Glaukos by 5.9% during the 4th quarter. MetLife Investment Management LLC now owns 29,561 shares of the medical instruments supplier's stock worth $4,432,000 after buying an additional 1,659 shares in the last quarter. State of Tennessee Department of Treasury lifted its position in shares of Glaukos by 5.9% during the 4th quarter. State of Tennessee Department of Treasury now owns 24,021 shares of the medical instruments supplier's stock worth $3,602,000 after buying an additional 1,328 shares in the last quarter. Finally, Stifel Financial Corp lifted its position in shares of Glaukos by 2.6% during the 4th quarter. Stifel Financial Corp now owns 4,341 shares of the medical instruments supplier's stock worth $651,000 after buying an additional 111 shares in the last quarter. Institutional investors own 99.04% of the company's stock.

Glaukos Stock Performance

GKOS stock traded down $2.37 during midday trading on Monday, reaching $91.78. 571,183 shares of the company's stock traded hands, compared to its average volume of 1,205,854. The company has a 50-day moving average price of $96.09 and a two-hundred day moving average price of $100.27. The firm has a market capitalization of $5.26 billion, a PE ratio of -55.62 and a beta of 0.78. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.69 and a current ratio of 5.51. Glaukos Corporation has a 52 week low of $77.10 and a 52 week high of $163.71.

Glaukos (NYSE:GKOS - Get Free Report) last issued its earnings results on Wednesday, July 30th. The medical instruments supplier reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.02. Glaukos had a negative return on equity of 8.59% and a negative net margin of 21.43%.The business had revenue of $124.12 million during the quarter, compared to the consensus estimate of $115.49 million. During the same quarter last year, the company earned ($0.52) EPS. The firm's revenue was up 29.7% compared to the same quarter last year. Glaukos has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that Glaukos Corporation will post -1.08 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. BTIG Research reissued a "buy" rating on shares of Glaukos in a research report on Monday, July 14th. William Blair raised shares of Glaukos to a "strong-buy" rating in a research report on Thursday, July 31st. Wells Fargo & Company lifted their target price on shares of Glaukos from $86.00 to $92.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 31st. UBS Group lifted their target price on shares of Glaukos from $125.00 to $134.00 and gave the stock a "buy" rating in a research report on Thursday, July 31st. Finally, Morgan Stanley dropped their target price on shares of Glaukos from $110.00 to $72.00 and set an "underweight" rating on the stock in a research report on Tuesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $127.42.

View Our Latest Research Report on Glaukos

About Glaukos

(Free Report)

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.

See Also

Institutional Ownership by Quarter for Glaukos (NYSE:GKOS)

Should You Invest $1,000 in Glaukos Right Now?

Before you consider Glaukos, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Glaukos wasn't on the list.

While Glaukos currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

The Market’s Next Big Winners? Start Here
5 High Short Interest Stocks to Buy Before November
HUGE Upside Ahead: The Fastest Growing ETFs in the Market

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines